G0-C14
Based on 2 publication(s) in Google Scholar
G0-C14 is a cationic lipid-like compound alkyl-modified polyamidoamine (PAMAM) dendrimer. G0-C14 involves in the preparation of a series of macrophage-targeted nanoparticles (NPs). NPs can be used for agent and vaccine delivery.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.0%
- CAS. Nr.: 1510653-27-6
- Formel: C106H216N10O10
- Molecular Weight:1790.91
-
Speicherung:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) G0-C14
More
Biologische Aktivität
G0-C14 exhibits strong entrapment of mRNA and pDNA with an encapsulation efficiency of above 95%[1].
Preparation of NPs[1]:
1.Dissolve PolyHCPT and DSPE-PEG3K in DMF to form a homogenous solution at a concentration of 5 mg/mL.
2.Prepare a mixture of 1 nmol of siRNA (0.1 nmol/μL aqueous solution) and G0-C14 (5 mg/mL in DMF) in different N/P molar ratios. Mixed them with the polyHCPT and DSPE-PEG3K solution.
3.Under vigorous stirring (1000 rpm), add the mixture dropwise to 5 mL of deionized water.
4.Transferr the formed NP dispersion to an ultrafiltration device.
5.Ccentrifug at room temperature (2800 rpm×8 min) to remove the organic solvent and free compounds.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 1510653-27-6
-
Appearance Oil
-
Molecular Weight 1790.91
-
Formel C106H216N10O10
-
Color Colorless to light yellow
-
SMILES
O=C(CCN(CCN(CCC(NCCN(CC(CCCCCCCCCCCC)O)CC(CCCCCCCCCCCC)O)=O)CCC(NCCNCC(CCCCCCCCCCCC)O)=O)CCC(NCCN(CC(CCCCCCCCCCCC)O)CC(CCCCCCCCCCCC)O)=O)NCCNCC(CCCCCCCCCCCC)O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
Structure-Activity Mapping of Intraperitoneal mRNA-LNPs: Decoupling Tumor and Liver Biodistribution in Pancreatic Cancer. [Abstract]2026 Mar 21:2026.03.20.712457. PMID: 41889911 -
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (55.84 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (1.40 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (1.40 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Li S, et al. Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. Biomaterials. 2020 Mar;234:119760. [Content Brief]
[2]. Chen Q, et al. Biodegradable nanoparticles decorated with different carbohydrates for efficient macrophage-targeted gene therapy. J Control Release. 2020 Jul 10;323:179-190. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.5584 mL | 2.7919 mL | 5.5838 mL | 13.9594 mL |
| 5 mM | 0.1117 mL | 0.5584 mL | 1.1168 mL | 2.7919 mL | |
| 10 mM | 0.0558 mL | 0.2792 mL | 0.5584 mL | 1.3959 mL | |
| 15 mM | 0.0372 mL | 0.1861 mL | 0.3723 mL | 0.9306 mL | |
| 20 mM | 0.0279 mL | 0.1396 mL | 0.2792 mL | 0.6980 mL | |
| 25 mM | 0.0223 mL | 0.1117 mL | 0.2234 mL | 0.5584 mL | |
| 30 mM | 0.0186 mL | 0.0931 mL | 0.1861 mL | 0.4653 mL | |
| 40 mM | 0.0140 mL | 0.0698 mL | 0.1396 mL | 0.3490 mL | |
| 50 mM | 0.0112 mL | 0.0558 mL | 0.1117 mL | 0.2792 mL |